Funding
The research was funded by Regeneron Pharmaceuticals, Inc. Authors who are employed by Regeneron Pharmaceuticals, Inc., also participated in the study design and the analysis and interpretation of findings. IQVIA was funded by Regeneron Pharmaceuticals, Inc., to conduct the research, perform the analysis and write this manuscript. All authors were involved at all stages of the manuscript in collaboration with the sponsor company. O Chassany has received fees from Novartis, Bristol-Myers Squibb, Takeda and IQVIA. A van Engen, L Lai, K Borhade and M Ravi are employed by IQVIA. J Harnett, C-I Chen and RGW Quek are employees and shareholders of Regeneron Pharmaceuticals, Inc. J Harnett is also a shareholder of Pfizer Inc. RGW Quek is also a shareholder of Amgen Inc. and Pfizer Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Medical writing support was provided by IQVIA and was funded by was funded by Regeneron Pharmaceuticals, Inc.
